Premium
Prognostic implications of miR‐16 expression levels in resected non‐small‐cell lung cancer
Author(s) -
Navarro Alfons,
Diaz Tania,
Gallardo Elena,
Viñolas Nuria,
Marrades Ramon M.,
Gel Bernat,
Campayo Marc,
Quera Angels,
Bandres Eva,
GarciaFoncillas Jesus,
Ramirez Jose,
Monzo Mariano
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21847
Subject(s) - medicine , microrna , oncology , lung cancer , proportional hazards model , taqman , oncogene , multivariate analysis , hazard ratio , survival analysis , cancer , stage (stratigraphy) , gastroenterology , real time polymerase chain reaction , gene , cell cycle , biology , confidence interval , paleontology , biochemistry
Background MicroRNAs are novel regulators of gene expression that are linked to the main oncogene networks, including the p53 pathway. p53 regulates the maturation process of miR‐16 and miR‐143. We analyzed the role as prognostic markers of miR‐16 and miR‐143 in 70 non‐small‐cell lung cancer (NSCLC) patients. Methods MicroRNAs were analyzed by TaqMan MicroRNA assays. Disease‐free survival (DFS) and overall survival (OS) were examined using Kaplan–Meier curves with log‐rank tests and the Cox proportional hazard model. Results When patients were classified in three groups according to their miR‐16 expression levels, those with normal levels had the best outcome while those with high levels had the worst. DFS was 22.4 months for patients with high levels, 71.8 months for those with normal levels, and 55.8 months for those with low levels ( P = 0.05). OS was 23.9 months for patients with high levels, 97.6 months for those with normal levels, and 63.5 months for those with low levels ( P < 0.001). In the multivariate analyses, high miR‐16 levels emerged as an independent prognostic factor for poor DFS ( P = 0.001) and OS (<0.001). Conclusions Our results provide the first hints that miR‐16 levels in tumor samples may be a prognostic marker in NSCLC. J. Surg. Oncol. 2011; 103:411–415. © 2010 Wiley‐Liss, Inc.